Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

Barbara A. Belli, Ph.D., Alan Dao, Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2011) 118 (21): 1538.

https://doi.org/10.1182/blood.V118.21.1538.1538

Published: 2011

Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

Barbara A. Belli, Ph.D., Alan Dao, B.S., Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2009) 114 (22): 2052.

https://doi.org/10.1182/blood.V114.22.2052.2052

Published: 2009

Journal Articles

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

Daniel Brigham, B.S., Barbara A. Belli, Ph.D., Michael Breider, Ph.D, DVM, Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2009) 114 (22): 2053.

https://doi.org/10.1182/blood.V114.22.2053.2053

Published: 2009

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Joyce James, PhD, Keith Pratz, Adam Stine, Julius L Apuy, PhD, Darren E Insko, PhD, Robert C Armstrong, Ph.D., Patrick P Zarrinkar, PhD, Donald Small, MD, PhD, Wendell Wierenga, PhD, Mark J. Levis, MD, PhD

Blood (2008) 112 (11): 2637.

https://doi.org/10.1182/blood.V112.11.2637.2637

Published: 2008

NARROW

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Email alerts

ASH Publications

American Society of Hematology

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only